Program of the 10th AMR Conference | March 3 - 4, 2026
March 3, 2026 Congress Center 2nd floor
08:45 – 10:30 | General Assembly | Room Osaka/Samarkand
Open only to members of the BEAM Alliance
11:00 – 12:00 | Plenary session | Room Sydney
Moderator: Florence Séjourné, AUROBAC Therapeutics & BEAM Alliance
Speakers:
Kevin Outterson, CARB-X
John Rex, AMR.Solutions
Evan Loh, Paratek Pharma
Hala Audi, Quantoom Biosciences
This 10th edition of the Conference also marks the 10-year anniversary of BEAM Alliance. And looking back more closely, it’s the 10-year milestone of many key events. Indeed, 2016 was a turning point in the fight against AMR. While the battle is far from over, we felt this was the right moment to pause and take stock.
Join the session “AMR: A decade in review” moderated by Florence Séjourné to revisit what the AMR landscape looked like in 2016 and to reflect on the major milestones since then. Together with our panelists Hala Audi, John Rex, Kevin Outterson and Evan Loh, we will map out the events that have shaped the past decade — across global policy & governance, epidemiology & burden, R&D and development milestones, as well as financing & incentives.
This story is our story. Come and share what has marked you most over the past 10 years.
12:00 – 13:30 | Lunch break
12:00 – 13:30 | Workshop | Room Rio
Title and speakers to be announced
13:30 – 14:30 | Plenary session | Room Sydney
Moderator: will be announced soon
Speakers:
Alex Tweddle, Angry Man Pictures
Laura Alonso Irujo, Spanish Agency for Medicines and Health Products (AEMPS)
Further speakers to be announced
15:00 – 16:00 | Parallel sessions
Room Sydney
Moderator: Peter Seiler, INCATE
Speakers:
Valeria Gigante, World Health Organization
Julia Djonova, Swissmedic
Neha Prasad, Rubrum Advising
Eric van der Helm, SNIPR Biome
When facing a persistent enemy, it sometimes takes thinking beyond conventional strategies.
That is exactly the promise of so-called non-traditional approaches, which encompass a wide range of actions against pathogens and open up new fronts in the fight against them.
But while they hold great potential, are they truly delivering on it?
The session “Non-traditional assets: the translation conundrum”, chaired by Peter Seiler, INCATE, will take a critical look at the progress, pitfalls, and future directions of non-traditional AMR solutions. It will explore key development roadblocks and challenge current positioning strategies:
🔹 Valeria Gigante will present an overview of the WHO pipeline analysis, highlighting recent trends and evolutions
🔹 Erik van der Helm will share SNIPR Biome’s journey — successes, setbacks, and key lessons learned
🔹 Neha Prasad, Rubrum Advising will explore strategic ways to demonstrate the clinical value of non-traditional antibacterials without compromising on stewardship or commercial viability.
🔹 Julia Djonova, SwissMedic will bring the regulator’s perspective on non-traditional antibacterials and discuss regulatory pathways to support access
A must-attend, one-stop session to understand where non-traditional approaches stand today – and where they are heading.
Room Singapore
Moderator: Yann Ferrisse, GARDP
Speakers:
Bennoit Hennion, Tamrisa
Leela Maitreyi, Bugworks
Morgane Vanbiervliet, Debiopharm
Innovation is what innovators do. But in AMR, scientific innovation alone is not enough. When markets are weak or missing, survival may depend on building truly innovative business models.
Join the session “Antimicrobial business models” moderated by Yann Ferrisse, GARDP, and highlighting inspiring ways to rethink how we finance development and create viable pathways to market.
🔹 Morgane Vanbiervliet will walk us through Debiopharm’s model, running AMR and oncology development in parallel
🔹 Benoit Hennion will share how Tamrisa combines the sales of established antimicrobials with the development of new ones
🔹 Leela Maitreyi will present Bugworks’ approach: focusing access and commercialization where the bugs actually are
And you — how are you thinking about your business model?
Come and discuss it with the experts.
Room Osaka/Samarkand
Moderator: Jan Posthumus, Basilea Pharmaceutica International
Speaker:
York Zöllner, Hamburg University of Applied Sciences
Antimicrobials save lives, protect populations, and buy us time—yet they remain undervalued, a disconnect that simply doesn’t make sense given their impact on patients and public health.
The session “Value of medicines: A Public Health & Payor Perspective” will invite us to put ourselves in the shoes of payors for an hour and better understand their world. Together with Jan Posthumus and York Zöllner, respectively Global Head Market Access and Market Research at Basilea and Professor of Health Economics at Hamburg University of Applied Sciences, we’ll unpack how payers think when valuing medicines in general—and antimicrobials in particular.
Among other things, the discussion will cover:
• Life-years gained and broader societal benefits (contagion control, AMR containment)
• Why “cheap and still working” distorts value assessment from a payor perspective
• The role of evidence challenges, emotions, and time
• Payor vs public health perspectives
• What remains unresolved
The incentivization for antimicrobials will not increase immediately after this session—but understanding each other’s constraints is a necessary first step for our two worlds to better connect.
16:00 – 16:30 | Poster presentations
16:30 – 17:30 | Parallel sessions
Room Sydney
Moderator: Christoph Dehio, NCCR AntResist
Speakers:
Jan Rybniker, University Hospital Cologne
Lauriane Cabon, F. Hoffmann-La Roche
Cesar de la Fuente, University of Pennsylvania
If you’re driven by innovation and scientific breakthroughs, this is a session you won’t want to miss. Join us for an inspiring discussion where leading scientists will share cutting-edge approaches that are reshaping the field.
Moderated by Christoph Dehio and NCCR AntiResist, this session brings together outstanding experts:
🔹 Jan Rybniker will explore the promise of antibacterial antibodies
🔹 Lauriane Cabon will highlight how organoid technologies can transform research and development
🔹 Cesar de la Fuente will showcase the immense potential of deep learning to accelerate antibiotic discovery
Expect thought-provoking insights, lively discussion, and the chance to connect with a community of forward-thinking researchers and innovators.
presented by
Room Singapore
Moderator: Carmen Coxon, Medicines and Healthcare products Regulatory Agency UK
Speakers:
Frédérique Vieville, 5QBD
Helerin Eiche, Estonia State Agency of Medicines
Frédéric Laurent, Hospices Civils de Lyon
Phage therapy has a century-long history, but integrating it into modern medicine raises unique regulatory and industrial challenges. Moderated by MHRA expert Carmen Coxon, this session explores how this long-standing biological approach is being reframed for contemporary clinical use—balancing efficacy, safety, and regulatory oversight.
You’ll hear from leading European experts addressing both recent regulatory advances and the critical gaps that still need to be bridged for phage therapies to scale:
🔹 Helerin Eiche, Estonian Health Agency: An overview of the newly released EMA guideline on bacteriophage medicinal products
🔹 Frédérique Vieville, 5QBD Biotech: From guidelines to practice: key regulatory signals emerging from European expert and industrial discussions on phage therapy
🔹 Frédéric Laurent, Hospices Civil de Lyon: The pivotal role of Phage Susceptibility Testing in the regulated use of phage products—and what still limits its implementation today
By the end of this session, participants will gain a global picture of the current European regulatory landscape for phage therapy, highlighting what is now better framed, what remains under discussion, and how regulatory thinking is progressively evolving.
Room Osaka/Samarkand
Moderator: Rachel Freeman, IQVIA
Speakers:
Bob de Vos, Nostics
Marco Caproni, TÜV SÜD
Kevin Lamkiewicz, SMA Development
presented by
18:00 – 19:30 | Pitch session | Room Sydney
Moderator: Guillermo Tramontin, Cavenagh Health
Running order of pitching companies:
will be published in February 2026
Organized by
Prize kindly sponsored by
19:30 – 21:00 | Evening reception
March 4, 2026 Congress Center 2nd floor
08:30 – 09:30 | Plenary session | Room Sydney
Moderator: Richard Alm, CARB-X
Speakers:
David Paterson, National University of Singapore
Drew Lewis, Innoviva Specialty Therapeutics
Claude Mabilat, bioMérieux
On paper, narrow-spectrum antimicrobials are widely seen as a key lever to curb the rise of resistance. In reality, their development and commercialisation remain challenging — and the latest WHO pipeline review even points to a slight decline in the number of these assets under development.
So how different is it to build a narrow-spectrum or species-specific therapy? And how dependent is success on access to rapid diagnostics?
The session “Narrow spectrum, wide impact,” moderated by Richard Alm, CARB-X, will unpack what it really takes to bring a targeted antimicrobial to market:
🔹 David Paterson, Advance-ID will share new perspectives on the unmet medical need for targeted approaches
🔹 Drew Lewis, Innoviva will walk through Xacduro’s journey and the key lessons learned
🔹 Claude Mabilat will highlight the role of bioMérieux and how the company views narrow-spectrum strategies from a diagnostics standpoint
Join this session to gain precise insights into how to develop a truly precise medicine. And that’s precisely what will be happening at the AMR Conference.
10:00 – 11:00 | Parallel sessions
Room Sydney
Moderator: will be announced soon
Speakers:
Radu Botgros, European Medicines Agency
Mihai Rotaru, EFPIA
Further speakers to be announced
Room Singapore
Moderator: Suzanne Edwards, Global AMR R&D Hub
Speakers:
Cesar Hernandez, Spanish Ministry of Health
Ana Burgos Gutierrez, European Commission
Aleksandra Opalska, European Commission
Luka Srot, IFPMA
Room Osaka/Samarkand
Moderator: Lucas Boeck, University of Basel
Speakers:
Hee-Jong Hwang, A&J Science
Nicola Ivan Lorè, Ospedale San Raffaele
Alexandra Aubry, Sorbonne University
11:00 – 11:30 | Poster presentations
11:30 – 12:30 | Plenary session | Room Sydney
Moderator: Damien Somé, GARDP
Speakers:
Jinyan Liu, Tigermed
Yonghong Xiao, Zhejiang University
Further speakers to be announced
12:30 – 12:45 | Plenary session | Room Sydney
Moderator: will be announced soon
Organized by
Prizes kindly sponsored by
12:45 – 14:00 | Lunch break
14:00 – 15:00 | Parallel sessions
Room Sydney
Moderator: Lisa Husband, BioVersys
Speakers:
Paul McGovern, Venatorx Pharmaceuticals
Rienk Pypstra, tranScrip
Evan Loh, Paratek Pharma
Late-stage clinical trials are the final step before market authorisation. But they are anything but a walk in the park. At this stage, failures are especially painful: the investments are massive, expectations are high, and in today’s market, there is rarely a second chance. No pressure.
So how can you get the design and execution of your late-stage trial right?
Don’t miss the session “Navigating the Complexities of Late-Stage Clinical Development,” moderated by Lisa Husband, BioVersys:
• Rienk Pypstra, tranScrip will provide an overview of the pitfalls to avoid and useful tips for designing and running late-stage trials.
• Evan Loh and Paul McGovern will share the lessons learned during the clinical studies of the VenatorX and Paratek portfolios.
You’ll walk away with practical insights to help you design smarter studies and avoid missing the final step on the way to approval.
Room Singapore
Moderator: Betsy Wonderly-Trainor, CARB-X
Speakers:
Martin Everett, AUROBAC Therapeutics
Michael Lobritz, F. Hoffmann-La Roche
Michael Hombach, F. Hoffmann-La Roche
Romney Humphries, Vanderbilt University Medical Center
Cameron Ball, Scout Health
It may seem obvious to link diagnostics and therapeutics – especially in AMR, where inappropriate treatment can further drive resistance. And yet, the reality is that players in these two fields don’t always collaborate as closely as they should. Developing a product is already challenging enough; coupling it with another can feel like an extra burden. But it isn’t. It’s essential.
The session “Better Together: Connecting Diagnostics and Therapeutics,” chaired by Betsy Wonderly Trainor from CARB-X, will explore how we can better connect these two worlds:
Romney Humphries (Vanderbilt University Medical Center) will provide a former industry and clinical collaborator’s perspective on the role of diagnostics in antimicrobial use and development.
Michael Lobritz and Michael Lombach (F. Hoffmann-La Roche) will explain how a large IVD and pharma company approaches antimicrobial drug and diagnostic test development in-house.
Martin Everett (AUROBAC Therapeutics) will share a small antimicrobial drug developer’s perspective on how diagnostics can support antibiotic development.
Cameron Ball (Scout Health) will share an example of collaboration from the perspective of a small diagnostics company on the simultaneous development of antibiotics and diagnostics.
Let’s all come together (and you’re invited too) to discuss how we can work better – together – for the benefit of everyone: companies on both sides, as well as patients, clinicians, and the healthcare system.
Room Osaka/Samarkand
Moderator: Delphine Croisier, Vivexia
Speakers:
Kristof van Emelen, Obulytix
Subhendu Basu, Telum Therapeutics
Yeung-Hyen Kim, iNtRON Biotechnology
Mark Beards, Santero Therapeutics
Ready to Discover the Future of Antimicrobial Innovation?
Antimicrobial resistance is a growing global challenge, but groundbreaking technologies are offering new hope. In the @AMR Conference session moderated by @Delphine Croisier @Vivexia, some of the brightest minds in the field will share transformative solutions you won’t want to miss:
• Mark Beards, Santero, will explain how inhibiting RSH enzymes offers a new paradigm for addressing biofilm-associated infections and persister cells that survive conventional antibiotic therapy.
• Yeung-Hyen Kim will present iNtRON’s novel endolysin-based solution, SAL200, for the treatment of infective endocarditis with high unmet medical needs.
• Subhendu Basu will discuss how Telum Therapeutics is leveraging its proprietary platform and synthetic biology to rethink innovation to outsmart antimicrobial resistance and fix the antibacterial market.
• Kristoph van Emelen will walk us through Obulytix’s Precision Lysin Therapeutics: engineered, serum‑stable biologics emerging from a scalable synthetic‑biology platform that selectively kill MDR Gram‑negative pathogens.
This is your chance to be at the forefront of innovation and learn from the pioneers shaping the future of antimicrobial solutions.
15:30 – 16:30 | Parallel sessions
Room Sydney
Moderator: Robert Kimbui, GARDP
Speakers:
Christopher Lim, PAHO Strategic Fund
Adnaan Ghanchi, ARMoR
Priya Balasubramaniam, Public Health Foundation India
Further speakers to be announced
Room Singapore
Moderator: Jennifer Schneider, Centauri Therapeutics
Speakers:
Sharon Hughes, IQVIA
Marc Lemonnier, Antabio
Chad Testa, Curza
Evolution is a natural process for adapting to new constraints – and it doesn’t apply only to living organisms. Organizations evolve too. This is especially true for small companies developing antimicrobials as they approach the clinical stage. For many, it is a true change of world, one that requires anticipation and preparation.
The session “Shaping Companies for Clinical Development Journeys”, chaired by Jennifer Schneider, Centauri, will explore how companies manage growth and transition to successfully advance into the clinic.
🔹 Chad Testa will share how Curza is preparing for the major leap into the clinical world while still navigating the challenge of fundraising
🔹 Marc Lemonnier will explain the operational, financial, and strategic choices that enabled Antabio to become a clinical-stage company
🔹 Sharon Hughes, IQVIA will present an overview of the support available to help companies through this transformation
A session built around experience-sharing between established companies and young ventures. Join us with your most pressing questions or most insightful recommendations – because sharing is helping.
Room Osaka/Samarkand
Moderator: Mateusz Hasso-Agopsowicz, World Health Organization
Speakers:
Juanjo Infante, Vaxdyn
Marta Vieira, ImmuneThep
Patricia Martin, LimmaTech Biologics
Is there a problem with vaccine development in AMR?
The pipeline remains worryingly thin, which means every failure has a major impact on our future ability to prevent resistant infections. Unfortunately, we’ve seen several high-profile setbacks recently.
In the session “Next-Gen Vaccines: Building Smart Strategies,” moderated by Mateusz Hasso-Agopsowicz (WHO), we’ll explore concrete approaches to de-risking the development of these critical assets:
🔹 Patricia Martin (LimmaTech) will highlight challenges in clinical development using an example of a vaccine development against S. Aureus.
🔹 Marta Vieira (Immunethep) will present how AI-driven design can help reduce the size of control groups in clinical studies.
🔹 Juanjo Infante will share key lessons learned from an observational study conducted by Vaxdyn.
17:00 – 18:00 | Plenary session | Room Sydney
Moderator: Marc Gitzinger, BioVersys & BEAM Alliance
Speakers:
Dame Sally Davies, UK Special Envoy on AMR
Nina Khanna, University Hospital Basel
Henry Skinner, AMR Action Fund
Alex Tasker, University of Bristol
18:00 – 19:00 | Farewell reception
BEAM Alliance program committee
Marc Gitzinger
Florence Séjourné
